ArticleBMC pregnancy and childbirth2026
Effect of preimplantation genetic testing for aneuploidy on pregnancy outcomes of patients with recurrent miscarriage: a retrospective study.
Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMiscarriage is a common complication of pregnancy, and it is defined as spontaneous pregnancy loss before the fetus reaches viability. However, there are no clear pathological factors identified as causes of recurrent miscarriage in some cases. Preimplantation genetic testing for aneuploidy (PGT-A) has been shown to have some advantages in the live birth rate in limited populations with a favorable prognosis. Hence, we investigated whether PGT-A improves pregnancy outcomes in patients with recurrent pregnancy loss.
methodsWe conducted a retrospective study including patients with a history of recurrent pregnancy loss from December 2021 to June 2022 receiving assisted reproduction therapy in the first medical center of the Chinese PLA General Hospital. The patients were divided into PGT-A and non-PGT-A groups, and we compared the pregnancy outcomes between the PGT-A and non-PGT-A groups.
resultsPGT-A significantly increased the clinical pregnancy rate per embryo transfer (ET) (58.7 vs. 32.3%, p = 0.023) and live birth rate per ET (50.0 vs. 25.8%, p = 0.034). However, there were no differences in biochemical pregnancy rates per ET (69.6 vs. 51.6%, P = 0.111), biochemical pregnancy loss rates (15.6 vs. 37.5%, p = 0.089), and miscarriage rate per clinical pregnancy (11.5 vs. 20.0%, p = 0.511) between the PGT-A and non-PGT-A groups.
conclusionsPGT-A was associated with significant improvements in clinical pregnancy and live birth rates in patients with recurrent pregnancy loss.
trial registrationThis study was registered at the Chinese Clinical Trial Registry (ChiCTR2200056991 http//www.chictr.org.cn/). Registration Date 20,220,225.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.